Financial Data Summary - The company reported preliminary financial data for the year 2025, with total operating revenue of 1,809.11 million yuan, a decrease of 202.51 million yuan, representing a decline of 10.07% year-on-year [1] - The net profit attributable to shareholders was 24.02 million yuan, reflecting a significant decline of 92.03% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 82.06 million yuan, down 71.44% [1] - Total assets at the end of the reporting period amounted to 4,293.09 million yuan, a decrease of 2.76% [1] - The equity attributable to the parent company was 2,697.97 million yuan, down 2.14% [1] Operational Performance and Financial Condition - The decline in operating profit, total profit, and net profit attributable to the parent company was primarily due to industry policy impacts and a short-term decrease in domestic market demand, leading to reduced operating revenue and gross margin [2] - The company experienced a loss in fair value from trading financial assets, specifically from shares in YunKang Group Limited [2] - The company identified and tested for impairment indicators on various assets as of December 31, 2025, and plans to recognize related impairment provisions based on prudence principles [2]
深圳市亚辉龙生物科技股份有限公司 2025年度业绩快报公告